Use of posaconazole in the treatment of invasive fungal infections

References

• McNeil MM, Nash SL, Hajjeh RA et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin. Infect. Dis.33(5), 641–647 (2001).
   PubMed Web of Science ®Google Scholar
• Pappas PG, Rex JH, Lee J et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin. Infect. Dis.37(5), 634–643 (2003).
   PubMed Web of Science ®Google Scholar
• Nucci M. Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis.16(6), 607–612 (2003).
   PubMed Web of Science ®Google Scholar
• Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis.39(4), 588–590 (2004).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood100(13), 4358–4366 (2002).
   PubMed Web of Science ®Google Scholar
• Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.34(7), 909–917 (2002).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA. Emerging fungal diseases. Clin. Infect. Dis.41(4), 521–526 (2005).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl J. Med.356(4), 348–359 (2007).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl J. Med.356(4), 335–347 (2007).
   PubMed Web of Science ®Google Scholar
• Frampton JE, Scott LJ. Posaconazole: a review of its use in the prophylaxis of invasive fungal infections. Drugs68(7), 993–1016 (2008).
   PubMed Web of Science ®Google Scholar
• Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann. Pharmacother.42(10), 1429–1438 (2008).
   PubMed Web of Science ®Google Scholar
• Cornely OA, Bohme A, Buchheidt D et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica94(1), 113–122 (2009).
   PubMed Web of Science ®Google Scholar
• Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin. Infect. Dis.45(12), 1610–1617 (2007).
   PubMed Web of Science ®Google Scholar
• Torres HA, Hachem RY, Chemaly RF, Kontoyiannis DP, Raad II. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect. Dis.5(12), 775–785 (2005).
   PubMed Web of Science ®Google Scholar
• Munayyer HK, Mann PA, Chau AS et al. Posaconazole is a potentinhibitor of sterol 14α-demethylation in yeasts and molds. Antimicrob. Agents Chemother.48(10), 3690–3696 (2004).
   PubMed Web of Science ®Google Scholar
• Xiao L, Madison V, Chau AS, Loebenberg D, Palermo RE, McNicholas PM. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14{α}-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob. Agents Chemother.48(2), 568–574 (2004).
   PubMed Web of Science ®Google Scholar
• Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy28(10), 1223–1232 (2008).
   PubMed Web of Science ®Google Scholar
• Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother.47(9), 2788–2795 (2003).
   PubMed Web of Science ®Google Scholar
• Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob. Agents Chemother.48(9), 3543–3551 (2004).
   PubMed Web of Science ®Google Scholar
• Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy27(12), 1627–1636 (2007).
   PubMed Web of Science ®Google Scholar
• Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin. Pharmacokinet.44(2), 211–220 (2005).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Cornely OA, Burchardt A et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother.50(2), 658–666 (2006).
   PubMed Web of Science ®Google Scholar
• Conte JE Jr, Golden JA, Krishna G, McIver M, Little E, Zurlinden E. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother.53(2), 703–707 (2009).
   PubMed Web of Science ®Google Scholar
• Ruping MJ, Albermann N, Ebinger F et al. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother.62(6), 1468–1470 (2008).
   PubMed Web of Science ®Google Scholar
• Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob. Agents Chemother.48(3), 804–808 (2004).
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol.57(2), 218–222 (2004).
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Calzetta A et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother.50(5), 1881–1883 (2006).
   PubMed Web of Science ®Google Scholar
• Jain R, Pottinger P. The effect of gastric acid on the absorption of posaconazole. Clin. Infect. Dis.46(10), 1627–1627 (2008).
   PubMed Web of Science ®Google Scholar
• Alffenaar J-WC, van Assen S, van der Werf TS, Kosterink JGW, Uges DRA. Omeprazole significantly reduces posaconazole serum trough level. Clin. Infect. Dis.48(6), 839–839 (2009).
   PubMed Web of Science ®Google Scholar
• Krishna G, Sansone-Parsons A, Martinho M et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Antimicrob. Agents Chemother.51(3), 812–818 (2007).
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Simon J et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother.51(2), 495–502 (2007).
   PubMed Web of Science ®Google Scholar
• Raad II, Hanna HA, Boktour M et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia22(3), 496–503 (2008).
   PubMed Web of Science ®Google Scholar
• Courtney R, Sansone A, Smith W et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J. Clin. Pharmacol.45(2), 185–192 (2005).
   PubMed Web of Science ®Google Scholar
• Raad II, Graybill JR, Bustamante AB et al. Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. Clin. Infect. Dis.42(12), 1726–1734 (2006).
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur. J. Pharma. Sci.21(5), 645–653 (2004).
   PubMed Web of Science ®Google Scholar
• Sansone-Parsons A, Krishna G, Martinho M et al. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy27(6), 825–834 (2007).
   PubMed Web of Science ®Google Scholar
• Moton A, Ma L, Krishna G, Martinho M, Seiberling M, McLeod J. Effects of oral posaconazole on the pharmacokinetics of sirolimus. Curr. Med. Res. Opin.25(3), 701–707 (2009).
   PubMed Web of Science ®Google Scholar
• Mantadakis E, Amoiridis G, Kondi A, Kalmanti M. Possible increase of the neurotoxicity of vincristine by the concurrent use of posaconazole in a young adult with leukemia. J. Pediatr. Hematol. Oncol.29(2), 130 (2007).
   PubMed Web of Science ®Google Scholar
• Eiden C, Palenzuela G, Hillaire-Buys D et al. Posaconazole-increased vincristine neurotoxicity in a child: a case report. J. Pediatr. Hematol. Oncol.31(4), 292–295 (2009).
   PubMed Web of Science ®Google Scholar
• Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J. Oncol. Pharm. Pract.15(3), 175–182 (2009).
   PubMedGoogle Scholar
• Morris MI. Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. Am. J. Health Syst. Pharm.66(3), 225–236 (2009).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Hollis RJ et al.In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole. Antimicrob. Agents Chemother.42(12), 3242–3244 (1998).
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Boyken L et al.In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn. Microbiol. Infect. Dis.48(3), 201–205 (2004).
   PubMed Web of Science ®Google Scholar
• Sabatelli F, Patel R, Mann PA et al.In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother.50(6), 2009–2015 (2006).
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Buitrago MJ, Monzon A, Rodriguez-Tudela JL. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother.50(3), 917–921 (2006).
   PubMed Web of Science ®Google Scholar
• Soczo G, Kardos G, McNicholas PM et al. Correlation of posaconazole minimum fungicidal concentration and time kill test against nine Candida species. J. Antimicrob. Chemother.60(5), 1004–1009 (2007).
   PubMedGoogle Scholar
• Torres-Narbona M, Guinea J, Martinez-Alarcon J, Pelaez T, Bouza E. In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. Antimicrob. Agents Chemother.51(3), 1126–1129 (2007).
   PubMed Web of Science ®Google Scholar
• Guembe M, Guinea J, Pelaez T, Torres-Narbona M, Bouza E. Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. Antimicrob. Agents Chemother.51(9), 3457–3458 (2007).
   PubMedGoogle Scholar
• Johnson EM. Issues in antifungal susceptibility testing. J. Antimicrob. Chemother.61(Suppl. 1), i13–i18 (2008).
   PubMedGoogle Scholar
• Rodriguez-Tudela JL, Alcazar-Fuoli L, Cuesta I et al. Clinical relevance of resistance to antifungals. Int. J. Antimicrob. Agents32(Suppl. 2), S111–S113 (2008).
   Google Scholar
• Iqbal NJ, Boey A, Park BJ, Brandt ME. Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods. Diagn. Microbiol. Infect. Dis.62(3), 348–350 (2008).
   PubMed Web of Science ®Google Scholar
• Cacciapuoti A, Loebenberg D, Corcoran E et al.In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob. Agents Chemother.44(8), 2017–2022 (2000).
   PubMed Web of Science ®Google Scholar
• Cacciapuoti A, Gurnani M, Halpern J, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicansin vivo. Antimicrob. Agents Chemother.49(2), 638–642 (2005).
   PubMed Web of Science ®Google Scholar
• Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob. Agents Chemother.48(10), 4063–4066 (2004).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob. Agents Chemother.48(10), 3715–3719 (2004).
   PubMed Web of Science ®Google Scholar
• Najvar LK, Cacciapuoti A, Hernandez S et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob. Agents Chemother.48(3), 758–764 (2004).
   PubMed Web of Science ®Google Scholar
• Cacciapuoti A, Halpern J, Mendrick C, Norris C, Patel R, Loebenberg D. Interaction between posaconazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob. Agents Chemother.50(7), 2587–2590 (2006).
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, Loebenberg D, Rinaldi MG, Patterson TF. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob. Agents Chemother.44(3), 780–782 (2000).
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother.45(3), 857–869 (2001).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Petraitis V, Petraitiene R et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis.188(2), 305–319 (2003).
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Krammes E, Sommer S et al. Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats. J. Antimicrob. Chemother.60(5), 1080–1084 (2007).
   PubMedGoogle Scholar
• O’Shaughnessy EM, Meletiadis J, Stergiopoulou T, Demchok JP, Walsh TJ. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother.58(6), 1168–1176 (2006).
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Petraitis V, Petraitiene R et al. Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation. J. Infect. Dis.194(7), 1008–1018 (2006).
   PubMed Web of Science ®Google Scholar
• Meletiadis J, Stergiopoulou T, O’Shaughnessy EM et al. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob. Agents Chemother.51(6), 2053–2064 (2007).
   PubMed Web of Science ®Google Scholar
• Lignell A, Lowdin E, Cars O et al. Characterization of the inhibitory effect of voriconazole on the fungicidal activity of amphotericin B against Candida albicans in an in vitro kinetic model. J. Antimicrob. Chemother.62(1), 142–148 (2008).
   PubMedGoogle Scholar
• Sun QN, Najvar LK, Bocanegra R, Loebenberg D, Graybill JR. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother.46(7), 2310–2312 (2002).
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Meis JF, Loebenberg D, Verweij PE. Activity of posaconazole in treatment of experimental disseminated zygomycosis. Antimicrob. Agents Chemother.47(11), 3647–3650 (2003).
   PubMed Web of Science ®Google Scholar
• Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob. Agents Chemother.43(3), 589–591 (1999).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Tijerina R, Najvar LK et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob. Agents Chemother.47(4), 1436–1438 (2003).
   PubMed Web of Science ®Google Scholar
• Graybill JR, Najvar LK, Johnson E et al. Posaconazole therapy of disseminated phaeohyphomycosis in a murine model. Antimicrob. Agents Chemother.48(6), 2288–2291 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med. Mycol.43(1), 91–95 (2005).
   PubMed Web of Science ®Google Scholar
• Al-Abdely HM, Najvar L, Bocanegra R et al. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum (“Ramichloridium mackenziei”). Antimicrob. Agents Chemother.44(5), 1159–1162 (2000).
   PubMed Web of Science ®Google Scholar
• Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob. Agents Chemother.49(5), 1701–1707 (2005).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cox GM, Dodge RK, Schell WA. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob. Agents Chemother.40(8), 1910–1913 (1996).
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Caselli F et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J. Antimicrob. Chemother.48(6), 769–773 (2001).
   PubMed Web of Science ®Google Scholar
• Barchiesi F, Schimizzi AM, Najvar LK et al. Interactions of posaconazole and flucytosine against Cryptococcus neoformans. Antimicrob. Agents Chemother.45(5), 1355–1359 (2001).
   PubMed Web of Science ®Google Scholar
• Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob. Agents Chemother.40(5), 1314–1316 (1996).
   PubMed Web of Science ®Google Scholar
• Lutz JE, Clemons KV, Aristizabal BH, Stevens DA. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob. Agents Chemother.41(7), 1558–1561 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Tijerina R, Najvar LK et al.In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob. Agents Chemother.46(5), 1352–1356 (2002).
   PubMed Web of Science ®Google Scholar
• Connolly P, Wheat J, Schnizlein-Bick C et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob. Agents Chemother.43(2), 322–328 (1999).
   PubMed Web of Science ®Google Scholar
• Connolly P, Wheat LJ, Schnizlein-Bick C et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob. Agents Chemother.44(10), 2604–2608 (2000).
   PubMed Web of Science ®Google Scholar
• Patterson TF, Kirkpatrick WR, White M et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore)79(4), 250–260 (2000).
   PubMed Web of Science ®Google Scholar
• Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect. Dis. Clin. North Am.16(4), 875–894, vi (2002).
   PubMed Web of Science ®Google Scholar
• Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am. J. Respir. Crit. Care Med.173(7), 707–717 (2006).
   PubMed Web of Science ®Google Scholar
• Perfect JR. Use of newer antifungal therapies in clinical practice: what do the data tell us? Oncology18(13 Suppl. 7), 15–23 (2004).
   Google Scholar
• Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J. Infect.55(4), 287–299 (2007).
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl J. Med.347(6), 408–415 (2002).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis.46(3), 327–360 (2008).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Raad I, Patterson TF et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis.44(1), 2–12 (2007).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lewis RE. Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management. Infect. Dis. Clin. North Am.20(3), 581–607, vi (2006).
   PubMed Web of Science ®Google Scholar
• Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis.41(5), 634–653 (2005).
   PubMed Web of Science ®Google Scholar
• Pagano L, Offidani M, Fianchi L et al. Mucormycosis in hematologic patients. Haematologica89(2), 207–214 (2004).
   PubMed Web of Science ®Google Scholar
• Lamaris GA, Lewis RE, Chamilos G et al. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis.198(2), 186–192 (2008).
   PubMed Web of Science ®Google Scholar
• Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin. Infect. Dis.41(1), 60–66 (2005).
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Lodewyck T, Lagrou K, Van Eldere J. Advances in the serological diagnosis of invasive Aspergillus infections in patients with haematological disorders. Mycoses50(Suppl. 1), 2–17 (2007).
   PubMed Web of Science ®Google Scholar
• Einsele H, Loeffler J. Contribution of new diagnostic approaches to antifungal treatment plans in high-risk haematology patients. Clin. Microbiol. Infect.14(Suppl. 4), 37–45 (2008).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case–control observational study of 27 recent cases. J. Infect. Dis.191(8), 1350–1360 (2005).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Hiemenz JW, Seibel NL et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin. Infect. Dis.26(6), 1383–1396 (1998).
   PubMed Web of Science ®Google Scholar
• Greenberg RN, Mullane K, van Burik JA et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob. Agents Chemother.50(1), 126–133 (2006).
   PubMed Web of Science ®Google Scholar
• van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP. Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin. Infect. Dis.42(7), e61–e65 (2006).
   PubMed Web of Science ®Google Scholar
• Raad II, Tarrand J, Hanna H et al. Epidemiology, molecular mycology, and environmental sources of Fusarium infection in patients with cancer. Infect. Control Hosp. Epidemiol.23(9), 532–537 (2002).
   PubMed Web of Science ®Google Scholar
• Torres HA, Raad, II, Kontoyiannis DP. Infections caused by Fusarium species. J. Chemother.15(Suppl. 2), 28–35 (2003).
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F et al.Fusarium infection in hematopoietic stem cell transplant recipients. Clin. Infect. Dis.38(9), 1237–1242 (2004).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin. Microbiol. Rev.20(4), 695–704 (2007).
   PubMed Web of Science ®Google Scholar
• Richardson M, Lass-Florl C. Changing epidemiology of systemic fungal infections. Clin. Microbiol. Infect.14(Suppl. 4), 5–24 (2008).
   PubMed Web of Science ®Google Scholar
• Nelson PE, Dignani MC, Anaissie EJ. Taxonomy, biology, and clinical aspects of Fusarium species. Clin. Microbiol. Rev.7(4), 479–504 (1994).
   PubMed Web of Science ®Google Scholar
• Elvers KT, Leeming K, Moore CP, Lappin-Scott HM. Bacterial-fungal biofilms in flowing water photo-processing tanks. J. Appl. Microbiol.84(4), 607–618 (1998).
   PubMed Web of Science ®Google Scholar
• Elvers KT, Leeming K, Lappin-Scott HM. Binary culture biofilm formation by Stenotrophomonas maltophilia and Fusarium oxysporum. J. Ind. Microbiol. Biotechnol.26(3), 178–183 (2001).
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Bodey GP, Hanna H et al. Outcome determinants of fusariosis in a tertiary care cancer center: the impact of neutrophil recovery. Leuk. Lymphoma45(1), 139–141 (2004).
   PubMed Web of Science ®Google Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years’ experience at a cancer center and implications for management. Blood90(3), 999–1008 (1997).
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer98(2), 315–319 (2003).
   PubMed Web of Science ®Google Scholar
• Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin. Infect. Dis.40(Suppl. 6), S401–S408 (2005).
   PubMed Web of Science ®Google Scholar
• Perfect JR, Marr KA, Walsh TJ et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin. Infect. Dis.36(9), 1122–1131 (2003).
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin. Infect. Dis.42(10), 1398–1403 (2006).
   PubMed Web of Science ®Google Scholar
• Wheat J. Endemic mycoses in AIDS: a clinical review. Clin. Microbiol. Rev.8(1), 146–159 (1995).
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transplant. Infect. Dis.1(4), 247–261 (1999).
   PubMedGoogle Scholar
• Torres HA, Rivero GA, Kontoyiannis DP. Endemic mycoses in a cancer hospital. Medicine81(3), 201–212 (2002).
   PubMed Web of Science ®Google Scholar
• Restrepo A, Tobon A, Clark B et al. Salvage treatment of histoplasmosis with posaconazole. J. Infect.54(4), 319–327 (2007).
   PubMed Web of Science ®Google Scholar
• Anstead GM, Corcoran G, Lewis J, Berg D, Graybill JR. Refractory coccidioidomycosis treated with posaconazole. Clin. Infect. Dis.40(12), 1770–1776 (2005).
   PubMed Web of Science ®Google Scholar
• Catanzaro A, Cloud GA, Stevens DA et al. Safety, tolerance, and efficacy of posaconazole therapy in patients with nonmeningeal disseminated or chronic pulmonary coccidioidomycosis. Clin. Infect. Dis.45(5), 562–568 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM, Fothergill AW, Sutton DA et al.In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med. Mycol.43(3), 281–284 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med. Mycol.47(1), 71–76 (2009).
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol.36(10), 2950–2956 (1998).
   PubMed Web of Science ®Google Scholar
• Negroni R, Tobon A, Bustamante B, Shikanai-Yasuda MA, Patino H, Restrepo A. Posaconazole treatment of refractory eumycetoma and chromoblastomycosis. Rev. Inst. Med. Trop. Sao Paulo47(6), 339–346 (2005).
   PubMedGoogle Scholar
• Herbrecht R, Letscher-Bru V, Fohrer C et al.Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B. Eur. J. Clin. Microbiol. Infect. Dis.21(11), 814–817 (2002).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Winston DJ, Mukwaya G et al. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis.34(12), 1648–1650 (2002).
   PubMed Web of Science ®Google Scholar
• Sanguineti A, Carmichael JK, Campbell K. Fluconazole-resistant Candida albicans after long-term suppressive therapy. Arch. Intern. Med.153(9), 1122–1124 (1993).
   PubMed Web of Science ®Google Scholar
• Newman SL, Flanigan TP, Fisher A, Rinaldi MG, Stein M, Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin. Infect. Dis.19(4), 684–686 (1994).
   PubMed Web of Science ®Google Scholar
• Marr KA, White TC, van Burik JH, Bowden RA. Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin. Infect. Dis.25(4), 908–910 (1997).
   PubMed Web of Science ®Google Scholar
• Revankar SG, Dib OP, Kirkpatrick WR et al. Clinical evaluation and microbiology of oropharyngeal infection due to fluconazole-resistant Candida in human immunodeficiency virus-infected patients. Clin. Infect. Dis.26(4), 960–963 (1998).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Skiest DJ, Nieto L et al. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin. Infect. Dis.42(8), 1179–1186 (2006).
   PubMed Web of Science ®Google Scholar
• Skiest DJ, Vazquez JA, Anstead GM et al. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection. Clin. Infect. Dis.44(4), 607–614 (2007).
   PubMed Web of Science ®Google Scholar
• Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin. Trials8(2), 86–97 (2007).
   PubMed Web of Science ®Google Scholar
• Weiler S, Lass-Flörl C, Auberger J et al. Triazole-resistant candidaemia following posaconazole exposure. Int. J. Antimicrob. Agents33(5), 494–495 (2009).
   PubMed Web of Science ®Google Scholar
• Thompson III GR, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS 2nd. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob. Agents Chemother.53(5), 2223–2224 (2009).
   PubMed Web of Science ®Google Scholar